Lung Carcinoma — Trials

Lung Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,130
Recruiting: 1,129
Ph III recruiting: 164
Growth YoY: +1.2%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,177)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05144997	Lorlatinib Continuation Study	active not recruiting	Phase 4	76	PfizerINDUSTRY	8	Sep 23, 2026	clinicaltrials
NCT06282874	Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases	active not recruiting	Phase 4	41	Guangdong Association of Clinical TrialsOTHER	1	Apr 9, 2026	clinicaltrials
NCT05160922